GSK’s Nucala Approved for COPD in EU, Elevates Monday Stocks
On February 8, 2026, the European Commission approved GSK’s Nucala (mepolizumab) for treating chronic obstructive pulmonary disease (COPD) in adults. This approval allows broader access for patients with uncontrolled COPD who have elevated blood eosinophils, particularly when current treatments are ineffective.
Market Response Following Nucala Approval
The market reacted positively to the announcement. GSK’s stock price rose to 2,198 pence, reflecting an increase of 0.8%. In the past week, the shares have climbed approximately 17%, and over the last year, they have surged nearly 49%. This growth has increased GSK’s total valuation to around £88 billion.
Investor Actions and Analyst Perspectives
- GSK Chairman Jonathan Symonds purchased 2,500 shares at £21.14 each on February 5, totaling £52,850.
- JP Morgan analyst Zain Ebrahim maintains a “Sell” rating for GSK, with a target price of 1,700 pence.
Investors are also keeping a close eye on upcoming dividend events, with GSK set to go ex-dividend on February 19. The record date is February 20, and payments are scheduled for April 9.
Clinical Trial Success Drives Approval
The approval of Nucala is supported by the MATINEE phase 3 trial results. This study demonstrated a significant improvement for patients, with a 21% reduction in yearly moderate or severe flare-ups. The trial showed a rate ratio of 0.79 compared to placebo. Moreover, flare-ups that necessitated emergency care or hospitalization also experienced a substantial decrease, with a rate ratio of 0.65.
Expert Commentary on Nucala’s Impact
Kaivan Khavandi, GSK’s global leader in Respiratory, Immunology & Inflammation R&D, emphasized the importance of Nucala as the first monthly biologic treatment for adults with uncontrolled COPD. However, Susanna Palkonen from the European Federation of Allergy and Airways Diseases Patients’ Associations highlighted the significant challenges still faced by COPD patients.
Looking Ahead: Market Implications
As trading resumes, analysts and investors will closely monitor the prescription rates for Nucala post-approval. The EU’s decision could potentially invigorate GSK’s stock momentum or be interpreted as a minor step in a lengthy reimbursement process across various regions. Additionally, the adoption of biologic treatments for COPD may face scrutiny from payers, particularly if traditional inhaler therapies continue to dominate physician preferences.
